32 MEN’S GROOMING 0 days 14 days 28 days 0 days
Figure 6: Lateral images of a subject’s eye at different time periods of the active treatment. Better skin elasticity
Reduced eye puffiness in men The ability of the new tetrapeptide to minimize the under-eyebags’ volume was assessed on a panel of 20 male volunteers between 30 and 65 years old. They applied a cream containing 1% tetrapeptide solution B on one eye contour and a placebo cream on the other, twice a day for 28 days. The volume of eyebags was assessed by means of a microtopography imaging system, and it was shown to significantly decrease after 14 and 28 days of treatment, with significant results versus placebo (Fig.4 and 5).
The overall appearance of the eye contour was visibly evaluated through digital photographs of the volunteers (Fig 6).
Finally, the test was completed with a self-assessment of the subjects regarding the product’s performance. The treatment with the peptide was positively rated by most of the volunteers, with 90% of them willing to recommend the product as an efficient anti-eyebag treatment.
Eye contour improvement The efficacy of the active ingredient was evaluated in vivo on the eye contour of a panel of 20 women between 18 and 65 years old, who applied a cream containing 10% tetrapeptide around the eyes, twice a day for 60 days. Different parameters were assessed before and after 15, 30 and 60 days of treatment.
Placebo 1% EYESERYL®
1.0 0.5 0.0 -0.5 -1.0 -1.5 -2.0 -2.5 -3.0 -3.5
peptide solution B -2.7% * Placebo
1% EYESERYL® solution
peptide
Figure 8: Eyebag volume reduction after 14 days of treatment (vs initial time: *p<0.05).
PERSONAL CARE EUROPE
Figure 9: Changes in the parameters L* (luminance) and ITA˚ (individual typological angle) after 14 days of treatment (vs initial time: *p<0.05, **p<0.01).
3.50 3.00 2.50 2.00 1.50 1.00 0.50 0.00
The changes in the overall elasticity of the skin after the active treatment were evaluated by means of a cutometer. After 30 days of the active treatment, skin elasticity showed to improve by 29.4% (p<0.0001), showing a further improvement of 35.0% (p<0.0001) after 60 days of application.
Skin moisturisation improvement The hydration of the skin was measured by corneometry. At the end of the treatment with the tetrapeptide a significant enhancement of almost 6% (p<0.0001) in skin hydration was obtained.
Under-eye puffiness reduction Digital pictures of the volunteers were obtained to assess the variation in the visibility of under-eye volume, which was also evaluated by a dermatologist that scored the reduction in puffiness at different time periods.
The tetrapeptide showed to reduce eyebags in 95% of the volunteers at the end of the treatment, obtaining a visible reduction in puffiness after only 15 days of treatment (Fig 7).
Anti-eyebags and anti-dark circles effect Another clinical test was performed on 17 female volunteers between 34 and 54 years old presenting puffiness and dark circles under the eyes. The subjects applied a cream with 1% tetrapeptide under one eye and a placebo cream under the other, twice a day
1% EYESERYL® peptide solution
3.0% *
15 days
Figure 7: Frontal images of a volunteer’s eye contour.
for 28 days. The variation in eyebags volume was evaluated by a fringe projection technique (Fig 8) and the dark circle pigmentation was assessed through chromametry studies (Fig 9) after 14 and 28 days.
Conclusion
The appearance of bulging bags and dark circles under the eyes can be caused by the deterioration of tissue and the accumulation of fluids due to an increased capillary permeability. Another factor involved in eyebags formation is the protrusion of the fat compartments under the eyes, men being particularly prone to suffer from such fat-related eyebags. EYESERYL®
peptide helps inhibit
1.0% *
glycation, vascular permeability and lipid accumulation, which are all contributors to a worsening of the under-eye region. Clinical efficacy data of this active ingredient shows that on the eye contour of male subjects, the ingredient helped reduce eyebag volume by after 14 and 28 days, with significant visible results and a good evaluation by the volunteers. When applied in vivo on female volunteers, it reduced the presence of eyebags and dark circles and it improved elasticity and moisturisation of the periorbital skin.
PC L* ITA* EYESERYL® is owned by The Lubrizol
Corporation or its affiliates. © 2019 The Lubrizol Corporation. All Rights Reserved.
February 2020
Variation in eyebag volume %
Variation in dark circles %
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
